Article thumbnail

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review

By Janet B. McGill
Publisher: Springer Nature
Year: 2014
DOI identifier: 10.1007/s13300-014-0063-1
OAI identifier:
Provided by: MUCC (Crossref)

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.